A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Patients with IGA Nephropathy Save

Date Added
July 23rd, 2019
PRO Number
Pro00085871
Researcher
Anand Achanti

List of Studies


Profiles_link
Keywords
Autoimmune disease, Inflammation, Kidney
Summary

The study is using cemdisiran compared to placebo injections to determine the safety and efficay of cemdisiran in treating IgA Nephropathy. The study includes a screening period (up to 90 days), 8 month treating period, and 52 week Open Label extension period. Injections occur monthly during the treatment period. Patients will be randomized 2:1 to the cemdisiran or placebo arms.

Institution
MUSC
Recruitment Contact
Kellean Van Cleef
8437928166
vancleef@musc.edu

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (Artemis-IGAN) Save

Date Added
May 14th, 2019
PRO Number
Pro00083397
Researcher
Anand Achanti

List of Studies


Profiles_link
Keywords
Drug Studies, Kidney
Summary

This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. OMS721 is an antibody, which is a type of protein that can bind to substances in the body. OMS721 is being studied because it blocks a key enzyme (a protein that causes specific chemical changes in the body) in the blood that may be responsible for causing the damage in IgA Nephropathy.
The study is approximately 23 visits over a period of 3 years. The study drug is administered via a 30-minute intravenous infusion once a week for 12 weeks. You will then be evaluated to determine your response to the drug and followed-up with regularly. Possible re-treatment is determined by the study doctor.

Institution
MUSC
Recruitment Contact
Kellean Van Cleef
843-792-8166
vancleef@musc.edu

Change_preferences

-- OR --

Create_login